Literature DB >> 17411025

Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 MAP kinase inhibitors.

Dominik R J Hauser1, Thomas Scior, David M Domeyer, Bernd Kammerer, Stefan A Laufer.   

Abstract

Based on the purine scaffold of ATP, derivatives of 6,9-diarylpurine-8-one were prepared and tested for their ability to inhibit p38 MAP kinase, a key enzyme in the cellular regulation of proinflammatory cytokines. The inhibitor design combines the purine system of the authentic cosubstrate ATP with various phenyl moieties to explore the selectivity for the two hydrophobic regions of the kinase's ATP-binding cleft. The present study indicates a new binding mode of our scaffold to p38 MAP kinase, which comprises the desired structural features of ATP and the N-phenyl-N-purin-6-yl ureas previously published by Wan et al. Combinations of Autodock and FlexX docking with different scoring functions were used to assess the postulated binding mode. The predictive power of different docking-scoring combinations was determined. The presented results may form a solid basis for further optimization cycles since our theoretical findings are consistent with our experimental binding data and supported by the literature.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17411025     DOI: 10.1021/jm061061w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  2 in total

1.  Sustainable synthesis and automated deposition: an accessible discovery screening library of fragment-like purines.

Authors:  Christoph Kamper; Katharina Korpis; Edgar Specker; Lennart Anger; Martin Neuenschwander; Patrick J Bednarski; Andreas Link
Journal:  Mol Divers       Date:  2012-08-14       Impact factor: 2.943

2.  3D-QSAR and molecular docking studies on fused pyrazoles as p38α mitogen-activated protein kinase inhibitors.

Authors:  Ping Lan; Zhi-Jian Huang; Jun-Rong Sun; Wei-Min Chen
Journal:  Int J Mol Sci       Date:  2010-09-17       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.